Sarcolemmal neuronal nitric oxide synthase defect in limb-girdle muscular dystrophy: An adverse modulating factor in the disease course?

Journal of Neuropathology and Experimental Neurology

Volumn 68, Issue 4, 2009, Pages 383-390

  Fanin, Marina ^a,b   Tasca, Elisabetta ^a,b   Nascimbeni, Anna Chiara ^a,b   Angelini, Corrado ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

Limb girdle muscular dystrophy; Nitric oxide synthase; NNOS; Sarcoglycan

Indexed keywords

ALPHA SARCOGLYCAN; BETA SARCOGLYCAN; CALPAIN; CAVEOLIN; DELTA SARCOGLYCAN; DYSFERLIN; GAMMA SARCOGLYCAN; NEURONAL NITRIC OXIDE SYNTHASE; CAV3 PROTEIN, HUMAN; CAVEOLIN 3; SARCOGLYCAN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CYTOSOL; DISEASE COURSE; GENE MUTATION; GENETIC DISORDER; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LIMB GIRDLE MUSCULAR DYSTROPHY; MUSCLE BIOPSY; MUSCULAR DYSTROPHY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN STABILITY; SARCOLEMMA; SCHOOL CHILD; BIOPSY; CLASSIFICATION; CYTOLOGY; ENZYMOLOGY; FEMALE; INFANT; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SKELETAL MUSCLE;

ADOLESCENT; ADULT; BIOPSY; CAVEOLIN 3; CHILD; CYTOSOL; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; NITRIC OXIDE SYNTHASE TYPE I; SARCOGLYCANS; SARCOLEMMA; YOUNG ADULT;

EID: 65349183975     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e31819cd612     Document Type: Article

References (39)

1. Ervasti JM, Campbell KP. Membrane organization of the dystrophin-glycorprotein complex. Cell.1991;66:1121-1131
2. Campbell KP.Three muscular dystrophies: Loss of cytoskeleton-extracellur matrix linkage. Cell 1995;80:675-679
3. Duggan DJ, Gorospe JR, Fanin M, Hoffman EP, Angelini C. Mutations in the sarcoglycan genes in patients with myopathy. N Engl J Med 1997; 336:618-624
4. Brenman JE, Chao DS, Xia H, et al. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 1995;82:743-752
5. Grozdanovic Z. NO message from muscle. Microsc Res Tech 2001;55: 148-153
6. Grady RM, Grange RW, Lau KS, et al. Role for alpha-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies. Nat Cell Biol 1999;1:215-220
7. Wehling M, Spencer MJ, Tidball JG. A nitric oxide synthase trans-gene ameliorates muscular dystrophy in mdx mice. J Cell Biol 2001;155: 123-131
8. Stamler JS, Meissner G. Physiology of nitric oxide in skeletal muscle. Physiol Rev 2001;81:209-237
9. Jaffrey SR, Snyder SH. PIN: An associated protein inhibitor of neuronal nitric oxide synthase. Science 1996;274:774-777
10. Sander M, Chavoshan B, Harris SA, et al. Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 2000;97: 13818-13823
11. Chang W, Iannaccone ST, Lau KS, et al. Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. Proc Natl Acad Sci U S A 1996;93:9142-9147
12. Crosbie RH. NO vascular control in Duchenne muscular dystrophy. Nat Med 2001;7:27-29
13. Rando TA. Role of nitric oxide in the pathogenesis of muscular dystrophies: A Btwo-hit[ hypothesis of the cause of muscle necrosis. Microsc Res Tech 2001;55:223-235
14. Kameya S, Miyagoe Y, Nonaka I, et al.α1-syntrophin gene disruption results in the absence of neuronal-type nitric oxide synthase at the sarcolemma but does not induce muscle degeneration. J Biol Chem 1999;274:2193-2200
15. Chao DS, Gorospe JR, Brenman JE, et al. Selective loss of sarcolemmal nitric oxide synthase in Becker muscular dystrophy. J Exp Med 1996; 184:609-618
16. Wells KE, Torelli S, Lu Q, et al. Relocalization of neuronal nitric oxide synthase (nNOS) as a marker for complete restoration of the dystrophin associated protein complex in skeletal muscle. Neuromuscul Disord 2003;13:21-31
17. Torelli S, Brown SC, Jimenez-Mallebrera C, et al. Absence of neuronal nitric oxide synthase (nNOS) as a pathological marker for the diagnosis of Becker muscular dystrophy with rod domain deletions. Neuropathol Appl Neurobiol 2004;30:540-545
18. Crosbie RH, Barresi R, Campbell KP. Loss of sarcolemma nNOS in sarcoglycan-deficient muscle. FASEB J 2002;16:1786-1791
19. Vorgerd M, Ricker K, Ziemssen F, et al. A sporadic case of rippling muscle disease caused by a de novo caveolin-3 mutation. Neurology 2001;57:2273-2277
20. Herrmann R, Straub V, Blank M, et al. Dissociation of the dystroglycan complex in caveolin-3 deficient limb girdle muscular dystrophy. Hum Mol Genet 2000;9:2335-2340
21. Archer JD, Vargas CC, Anderson JE. Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort. FASEB J 2006;20:738-740
22. Wehling-Henricks M, Jordan MC, Roos KP, Deng B, Tidball JG Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium. Hum Mol Genet 2005;14:1921-33
23. Wang B, Li J, Qiao C, et al. A canine minidystrophin is functional and therapeutic in mdx mice. Gene Ther 2008;15:1099-1106
24. Crosbie RH, Straub V, Yun HY, et al. Mdx muscle pathology is independent of nNOS perturbation. Hum Mol Genet 1998;7:823-829
25. Wehling M, Stull JT, McCabe TJ, Tidball JG. Sparing of mdx extraocular muscles from dystrophic pathology is not attributable to normalized concentration or distribution of neuronal nitric oxide synthase. Neuromuscul Dis 1998;8:22-29
26. Anderson LVB, Davison K. A multiplex western blotting system for the analysis of muscular dystrophy proteins. Am J Pathol 1999;154:1017-1022
27. Fanin M, Angelini C. Regeneration in sarcoglycanopathies: Expression studies of sarcoglycans and other muscle proteins. J Neurol Sci 1999; 165:170-177
28. Hoshino S, Ohkoshi N, Ishii A, Shoji S. The expression of nNOS and dystrophin in rat regenerating muscle. J Muscle Res Cell Motil 2002;23: 139-145
29. Punkt K, Schering S, Loffler S, et al. Nitric oxide synthase is up-regulated in muscle fibers in muscular dystrophy. Biochem Biophys Res Comm 2006;348:259-264 (Pubitemid 44163508)
30. Thomas GD, Sander M, Lau KS, Huang PL, Stull JT, Victor RG. Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc Natl Acad Sci U S A 1998;95: 15090-15095
31. Hainsey TA, Senapati S, Kuhn DE, Rafael JA. Cardiomyopathic features associated with muscular dystrophy are independent of dystrophin absence in cardiovasculature. Neuromuscul Dis 2003;13: 294-302
32. Wheeler MT, Allikian MJ, Heydemann A, et al. Smooth muscle cellVextrinsic vascular spasm arises from cardiomyocyte degeneration in sarcoglycan-deficient cardiomyopathy. J Clin Invest 2004; 113:668-675
33. Melacini P, Fanin M, Duggan DJ, et al. Heart involvement in muscular dystrophies due to sarcoglycan gene mutations. Muscle Nerve 1999;22: 473-479
34. Fanin M, Melacini P, Boito C, Pegoraro E, Angelini C. LGMD2E patients risk developing dilated cardiomyopathy. Neuromuscul Dis 2003;13:303-309
35. Coral-Vazquez R, Cohn RD, Moore SA, et al. Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: A novel mechanism for cardiomyopathy and muscular dystrophy. Cell 1999;98: 465-474
36. Araishi K, Sasaoka T, Imamura M, et al. Loss of the sarcoglycan complex and sarcospan leads to muscular dystrophy in beta-sarcoglycan deficient mice. Hum Mol Genet 1999;8:1589-1598
37. Durbeej M, Cohn RD, Hrstka RF, et al. Disruption of the A-sarcoglycan gene reveals pathogenetic complexity of limb-girdle muscular dystrophy type 2E. Mol Cell 2000;5:141-151
38. Heydemann A, Huber JM, Kakkar R, Wheeler MT, McNally EM. Functional nitric oxide synthase mislocalization in cardiomyopathy. J Mol Cell Cardiol 2004;36:213-223
39. Cohn RD, Durbeej M, Moore SA, et al. Prevention of cardiomyopathy in mouse models lacking the smooth muscle sarcoglycan-sarcospan complex. J Clin Invest 2001;107:1-7